SECOND SIGHT MEDICAL PRODUCTS INC EYES Cash Flow

Second sight medical products inc (EYES)

CashFlow / Quarterly

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
-7,868	-7,584	-8,440	-9,700	-8,858	-8,522	-7,961	-9,753	-7,409	-6,716	-6,843	-7,548	-10,370	-8,489	-8,504	-5,816	-5,473	-4,666	-9,874	-4	-13,576	-7,644	-7,541	-6,438
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment
104	97	97	99	106	107	111	111	112	116	116	113	121	108	104	99	104	73	157	0	69	64	67	77
Stock-based compensation
482	686	859	898	800	877	627	1,285	963	905	935	981	786	899	736	946	769	857	1,060	0	359	292	227	595
Non-cash lease expense
4	3	4	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,440
Non-cash interest accrued on convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-296	-558	-551	-545
Bad debt expense
-	-	-	-	-	-	-	-	-14	-92	16	-52	67	0	191	0	-	-	-	-	-	-	-	-
Excess inventory reserve
-	-	-	-	448	110	170	-109	-1,375	-275	-743	-713	2,117	1,088	1,523	0	-	-	-	-	-	-	-	-
Impairment charge
-	-	-	2,424	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued for services
-	-	-	-	0	0	44	65	67	65	65	65	66	65	66	75	-	-	-	-	-	-	-	-
Common stock issuable for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-	-	-	-
Common stock issuable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Changes in operating assets and liabilities:
Accounts receivable
192	-362	27	95	-581	461	274	-1,374	1,102	-393	250	454	-81	-247	40	-667	193	99	500	0	-38	286	-135	126
Inventories
533	-550	-422	786	96	135	968	-21	-1,913	-68	-854	-1,033	-176	-493	-157	816	72	1,333	1,082	0	522	1,158	785	908
Prepaid expenses and other assets
-60	-425	-349	-236	896	-130	-177	16	332	-248	-121	108	114	-23	-273	-196	322	-381	185	0	104	185	212	53
Accounts payable
-35	-129	-346	297	-241	324	-386	857	-120	229	-259	-269	462	23	-36	-3	166	213	-181	-0	80	-268	202	183
Accrued expenses
-190	-474	249	-57	527	-103	10	-354	98	27	51	155	421	-64	114	-427	187	-36	504	0	246	386	30	84
Accrued compensation expenses
235	256	126	-609	-271	513	372	-534	345	444	216	8	-454	379	-20	-374	-181	617	270	0	-	-	-	-
Accrued compensation expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-69
Accrued clinical trial expenses
-27	-304	21	84	-2	-139	133	161	156	-9	-9	12	74	4	-50	-15	59	47	21	-0	-2	0	0	0
Contract liabilities
-219	1	334	53	58	-150	99	114	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	0	-386	282	-	-74	-57	-4	-462	-121	304	0	-6	233	293	11
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	-	-104	-	-649	-525	-567	-	-	-	-	-	-	-	-
Net cash used in operating activities
-7,386	-6,458	-6,635	-7,150	-7,731	-7,455	-7,846	-6,778	-6,714	-4,678	-5,956	-6,599	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,068	-6,039	-	-4,759	-9,887	-5	-1,094	-5,718	-5,621	-4,656
Cash flows from investing activities:
Purchases of property and equipment
99	230	127	37	19	28	48	68	84	30	62	89	84	111	199	96	184	286	291	0	117	161	189	91
Proceeds from money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	6,148	-13,909	5,941	-	-	-	-	-	-	-	-
Proceeds from money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-	-2,382	-1,051	-4,480
Net cash used in investing activities
-99	-230	-127	-37	-19	-28	-48	-68	-84	-30	-62	-89	1,736	6,037	-14,108	5,845	5,496	4,493	7,523	4	-33,419	2,220	862	4,389
Proceeds from exercise of common stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	387	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants
106	0	0	34,399	6,997	4,969	9,978	3,992	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from rights offering
-	-	-	-	-	-	-	-	-	0	0	19,688	-	0	19,483	0	-	-	-	-	-	-	-	-
Net proceeds from sale of common stock
-	-	-	-	-	-	-	-	20,772	0	0	0	-	-	-	-	-	-	-	-	-	1,519	6,878	700
Proceeds from repayment of note receivable
-	-	-	-	-	-	-	-	-	1	0	1	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of options, warrants and employee stock purchase plan options
-	-	-	-	248	0	402	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Payment of employment taxes related to stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from exercise of options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3
Repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by financing activities
352	0	238	34,399	7,245	4,969	10,380	4,007	1,289	1	189	19,689	153	0	19,912	387	407	197	2,154	0	34,226	1,589	7,284	703
Effect of exchange rate changes on cash and cash equivalents
-2	-11	3	-1	-	-	-24	14	4	-78	67	15	4	3	-11	27	-35	-70	-1	-0	-69	-61	-30	-45
Net increase (decrease)
-	-	-6,521	27,211	-	-	2,462	-2,825	-5,505	-4,785	-5,762	13,016	-5,123	93	-275	220	-29	-139	-212	0	-357	-1,969	2,494	390
Common stock issued in connection with finder fees paid on private placements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	74	341	35
Fair value of stock options issued for services rendered in connection with rights offering
-	-	-	-	-	-	-	-	0	0	0	20	0	0	26	27	-	-	-	-	-	-	-	-